RecruitingPHASE2, PHASE3NCT07441876
A Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Studying Achondroplasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioMarin Pharmaceutical
- Principal Investigator
- Medical Director, PhDBioMarin Pharmaceutical
- Intervention
- BMN 333(drug)
- Enrollment
- 160 enrolled
- Eligibility
- 2-17 years · All sexes
- Timeline
- 2026 – 2029
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07441876 on ClinicalTrials.govOther trials for Achondroplasia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07388966Prospective Longitudinal Monocentric Study to Measure Limb Movement in Patients With FGFR3-related Skeletal DysplasiaSYSNAV
- RECRUITINGPHASE2NCT07169279Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)QED Therapeutics, a BridgeBio company
- RECRUITINGNCT07301463A Study in Children With AchondroplasiaAbbisko Therapeutics Co, Ltd
- RECRUITINGPHASE2NCT06842355A Study of TYRA-300 in Children With Achondroplasia: BEACH301Tyra Biosciences, Inc
- RECRUITINGPHASE2NCT06732895A Clinical Trial to Evaluate Efficacy and Safety of Navepegritide in Adolescents (12 - 18 Years of Age) With Achondroplasia.Ascendis Pharma A/S
- RECRUITINGPHASE3NCT06926491Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）Kyowa Kirin Co., Ltd.
- ACTIVE NOT RECRUITINGPHASE2NCT06433557A Phase 2 Clinical Trial to Evaluate Efficacy, Safety, and Tolerability of Navepegritide in Combination With Lonapegsomatropin in Children With AchondroplasiaAscendis Pharma Growth Disorders A/S
- RECRUITINGPHASE2NCT06079398A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With AchondroplasiaAscendis Pharma A/S